RPRX · NASDAQ
Royalty Pharma plc
$63.86 +0.09 (+0.13%)
Company overview
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates addressing various therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $28.4B
- Employees
- 75
- Headquarters
- New York City, NY
- Website
- royaltypharma.com
- CEO
- Pablo Legorreta
- Listed
- June 16, 2020
- P/E
- 25.92
- Dividend yield
- 1.58%
Company financials
- Revenue
- $2.4B
- Gross profit
- $2.4B
- Operating income
- $1.7B
- EBITDA
- $1.8B
- Net income
- $828M
- EPS
- $2.46
- Total assets
- $19.8B
- Total debt
- $9B
- Gross margin
- 99.95%
- Net margin
- 33.91%
- Earnings yield
- 3.86%
No geographic segmentation.
Showing FY 2025
RPRX
1D
NASDAQ
O62.34H63.84L62.34C63.75+1.60 (+2.57%)Vol2.81M